According to the New York Times, Elon Musk's drug use was reportedly more extensive than previously known, including heavy ketamine use affecting his health, as well as occasional use of Ecstasy and psychedelic mushrooms. The report, citing private messages and interviews, indicates this occurred partly during the period when Musk was supporting Donald Trump's presidential campaign, raising concerns among those close to him. This revelation could impact investor confidence in Tesla and SpaceX, given Musk's crucial role in both companies.
A New York Times report alleges that Elon Musk, CEO of Tesla Inc. (TSLA) and SpaceX, engaged in heavier drug use than previously known, including substantial ketamine consumption reportedly affecting his physical health, alongside occasional use of Ecstasy and psychedelic mushrooms, particularly during his involvement in Donald Trump's presidential campaign. These revelations, sourced from private messages and individuals familiar with Musk, have reportedly caused concern among his associates. For investors, this news carries significant implications, primarily escalating key-person risk for Tesla, as reflected by a strongly negative sentiment score of -0.7 specifically for TSLA and an overall market impact score of 0.65. The situation directly spotlights critical "Management & Governance" concerns, potentially undermining investor confidence in Musk's leadership stability and judgment, which are pivotal to Tesla's valuation and strategic execution.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.70
Ticker Sentiment
